vida: extract claims from 2026-05-05-npr-glp1-eating-disorders-not-well-understood

- Source: inbox/queue/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Atypical anorexics meet diagnostic criteria for anorexia nervosa despite normal or elevated BMI, making them appear as ideal GLP-1 candidates to prescribers using BMI-based screening alone
+confidence: experimental
+source: Dr. Kim Dennis (eating disorder specialist), NPR investigation
+created: 2026-05-05
+title: GLP-1 prescribing creates systematic screening gap for atypical anorexia because normal BMI masks active restrictive psychopathology
+agent: vida
+sourced_from: health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
+scope: structural
+sourcer: "NPR (@NPRHealth)"
+supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population"]
+---
+
+# GLP-1 prescribing creates systematic screening gap for atypical anorexia because normal BMI masks active restrictive psychopathology
+
+Dr. Kim Dennis identifies atypical anorexia as a specific high-risk population for GLP-1 harm that standard screening protocols fail to detect. Atypical anorexia nervosa is characterized by meeting full diagnostic criteria for anorexia nervosa—including restrictive eating patterns, fear of weight gain, and body image disturbance—while maintaining a BMI in the normal or overweight range. This creates a dangerous screening gap: these patients appear as textbook GLP-1 candidates based on BMI criteria alone, but have active eating disorder psychopathology that GLP-1's appetite suppression will exacerbate. The article notes that 'nearly a tenth of people will meet the clinical benchmarks of an eating disorder at some point in their lives,' creating substantial overlap with the obesity treatment population. Dr. Samantha DeCaro emphasizes that eating disorders involve 'emotional, relational, and biological drivers' that weight loss alone does not address. The structural problem is that BMI-based eligibility screening—the primary gate for GLP-1 access—is precisely the metric that makes atypical anorexia invisible. This is distinct from general eating disorder risk: it's a population-specific screening failure where the diagnostic tool (BMI) actively obscures the contraindication.

domains/health/glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbou
 scope: structural
 sourcer: NBC News
 supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
-related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
+related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap"]
 ---
 
 # Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
@@ -24,3 +24,10 @@ Dr. Aaron Keshen reports EDs developing 'in people who take drugs as prescribed'
 **Source:** PMC12694361 systematic review
 
 Systematic review characterizes current evidence state as 'low-to-moderate confidence throughout' with BED/BN findings 'preliminary' and restrictive ED evidence 'scarce and inconclusive.' Explicitly identifies methodological limitations: 'most studies are short-term, narrowly sampled, and methodologically limited.' Long-term follow-up data (>1 year) identified as missing.
+
+
+## Extending Evidence
+
+**Source:** NPR investigation, absence of cohort data
+
+Article provides no quantitative incidence data, only qualitative expert opinion. Curator notes: 'The article is entirely qualitative/expert opinion—no cohort data.' This confirms that the evidence gap is not just about causality but about basic epidemiological measurement—we don't have population-level data on eating disorder incidence in GLP-1 users.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -38,3 +38,10 @@ Clinicians describe progression from beneficial appetite suppression to patholog
 **Source:** Northwestern Medicine JCI 2025, Dr. Beutler
 
 Northwestern's AgRP neuron silencing mechanism provides the neurological explanation for subtype-specific risk. For restrictive eating disorders (anorexia nervosa, atypical anorexia), semaglutide removes the AgRP-mediated biological alarm that would normally trigger compensatory hunger during dangerous weight loss. For binge eating disorder, the same mechanism may be protective by reducing the hedonic drive to eat. The 'double whammy' of fullness signaling PLUS starvation-protection removal creates asymmetric risk profiles across ED subtypes.
+
+
+## Supporting Evidence
+
+**Source:** NPR, behavioral health specialist interviews
+
+Dr. DeCaro and Dr. Dennis focus exclusively on restrictive eating disorder risk (anorexia nervosa, atypical anorexia) with no discussion of binge eating disorder or purging pathways. The curator notes: 'No discussion of GI-induced purging specifically—the behavioral health experts interviewed focused entirely on restrictive disorders, not purging/bulimic pathway.' This confirms that clinical expert consensus identifies restrictive subtypes as the primary harm pathway.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -59,3 +59,10 @@ Timmerman Report documents that semaglutide labels do not include warnings for r
 **Source:** FDA oral Wegovy label, January 2026
 
 FDA label for oral Wegovy contains NO eating disorder warning or screening requirement despite known pharmacovigilance signal (aROR 4.17-6.80). Label includes standard thyroid C-cell tumor boxed warning but explicitly REMOVED suicidal behavior/ideation warning in 2026 review after finding no causal link. This regulatory asymmetry—removing psychiatric warnings while maintaining zero ED action—confirms the screening gap is structural/regulatory, not knowledge-based.
+
+
+## Extending Evidence
+
+**Source:** NPR, Dr. Samantha DeCaro and Dr. Kim Dennis interviews
+
+Dr. DeCaro and Dr. Dennis provide clinical expert consensus that screening protocols exist (SCOFF questionnaire plus history plus behavioral assessment) but are not implemented due to structural barriers, not knowledge gaps. The article notes 'easy online access with little screening creates vulnerability in susceptible populations,' confirming that the gap is operational infrastructure, not clinical uncertainty about what to screen for.

domains/health/glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population.md

@@ -17,3 +17,10 @@ related: ["SDOH interventions show strong ROI but adoption stalls because Z-code
 # GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population
 
 Despite evidence of elevated eating disorder risk in GLP-1 users with prior mental health conditions, the prescribing infrastructure lacks systematic screening protocols. Timmerman Report documents that: (1) no standard protocol for eating disorder screening before prescribing exists, (2) no safety database for monitoring GLP-1-induced eating disorders is operational, (3) no required clinical follow-up structure is in place, and (4) semaglutide labels do not include warnings for restrictive eating disorder risk. The article quotes an unspecified source stating 'physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave.' This represents a structural gap where the clinical knowledge exists (prior mental health history doubles risk) but the operational infrastructure to act on it does not. The parallel to Z-code SDOH documentation is direct: screening would catch risk but there's no reimbursement or requirement to perform it.
+
+
+## Supporting Evidence
+
+**Source:** NPR investigation, curator analysis
+
+Article implicitly confirms reimbursement gap by noting that screening is not occurring despite identified at-risk populations. The curator notes connect this to 'value-based care transitions stall at the payment boundary'—screening costs are not reimbursed, creating the same structural barrier that blocks SDOH intervention.

domains/health/glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Expert consensus frames GLP-1 eating disorder risk as interaction between drug mechanism and sociocultural context, not direct pharmacological causation
+confidence: experimental
+source: Robyn Pashby (OAC board), Dr. Samantha DeCaro, NPR synthesis
+created: 2026-05-05
+title: GLP-1 harm risk is mediated by cultural weight stigma and pressure rather than pharmacological properties alone
+agent: vida
+sourced_from: health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
+scope: causal
+sourcer: "NPR (@NPRHealth)"
+supports: ["glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+related: ["glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+---
+
+# GLP-1 harm risk is mediated by cultural weight stigma and pressure rather than pharmacological properties alone
+
+Robyn Pashby articulates the dual-truth framework: 'GLP-1s are legitimate evidence-based treatments for obesity, but they also sit inside our culture, which has intense weight pressure, weight stigma and eating disorder risk.' This positions harm not as inherent to the drug but as emergent from the interaction between pharmacological appetite suppression and a cultural environment that valorizes thinness and stigmatizes weight. Dr. DeCaro emphasizes that GLP-1s are 'potentially more harmful' than prior weight-loss drugs because they 'make it harder for people to nourish themselves regularly, or tune into their natural hunger cues'—but this harm manifests specifically in individuals with 'emotional, relational, and biological drivers' that predispose to eating disorders. The article identifies at-risk groups as 'those with prior body-weight trauma/bullying, atypical anorexia, genetic predisposition to reduced satiety, men with eating disorders (underdiagnosed), people obtaining online without clinical evaluation.' This is a fundamentally different causal model than direct pharmacological induction: the drug creates vulnerability that cultural context converts into harm. The mechanism is cultural amplification of pharmacological effect, not pharmacological determinism. This explains why the same drug produces different outcomes in different populations and why behavioral/psychological factors are 'primary determinants of who is harmed.'

inbox/archive/health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md

@@ -7,10 +7,13 @@ date: 2026-02-04
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, eating-disorders, semaglutide, wegovy, anorexia, atypical-anorexia, screening]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content